The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

EastGroup Properties, Inc.  (the "Company", "we", "our", "us" or "EastGroup") announced today its recent business activity. As ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs contributed significantly to its top-line growth in 2024. Lilly is also making ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab. JAIN: In…December 2023, pirtobrutinib ...

“My laboratory, almost ten years ago, discovered that this drug, Ventecolax, may enhance the activity against leukemia cells,” says Dr. Raoul Tibes, Director, Clinical Leukemia Program, NYU Langone ...

We increased 3 percentage points in share of market in Q4 2024. Jaypirca worldwide revenue was $114 million, adding another solid quarter of sequential revenue growth. Worldwide onboard revenue ...

We increased 3 percentage points in share of market in Q4 2024. Jaypirca worldwide revenue was $114 million, adding another solid quarter of sequential revenue growth. Worldwide Omvoh revenue ...

The non-incretin portfolio also grew by 20%, with notable contributions from Verzenio and Jaypirca. International markets, including Europe, Japan, and China, showed robust growth, with Mounjaro ...